Cravens & Co Advisors
LLY icon

Cravens & Co Advisors’s Eli Lilly LLY Stock Holding History

Cravens & Co Advisors’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.46M Buy
1,265
+29
+2% +$34.2K 0.99% 26
2026
Q2 		$1.48M Sell
1,236
-271
-18% -$277K 1% 22
2026
Q1 		$1.39M Buy
1,507
+3
+0.2% +$3.04K 0.9% 26
2025
Q4 		$1.62M Sell
1,504
-15
-1% -$14.3K 1.06% 24
2025
Q3 		$1.16M Sell
1,519
-15
-1% -$11.2K 0.79% 30
2025
Q2 		$1.2M Buy
+1,534
New +$1.19M 0.89% 27

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $104B AUM 51.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Cravens & Co Advisors's LLY Position: Q3 2026 in Review

Cravens & Co Advisors increased its Eli Lilly (LLY) stake by 2.3% in Q3 2026, buying an estimated $34.2K and bringing the position to 1,265 shares worth $1.46M. The position accounts for 0.99% of the portfolio, ranked #26.

Cravens & Co Advisors first reported a position in LLY in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.62M in Q4 2025. 4,106 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Cravens & Co Advisors held 1,265 shares of Eli Lilly worth $1.46M as of Q3 2026.
  • Cravens & Co Advisors bought 29 Eli Lilly shares in Q3 2026, an estimated $34.2K.
  • Eli Lilly made up 0.99% of Cravens & Co Advisors's portfolio in Q3 2026, its #26 holding.
  • Cravens & Co Advisors first reported a position in Eli Lilly in Q2 2025 and has held it in 6 quarters since.
  • Cravens & Co Advisors's Eli Lilly position peaked at $1.62M in Q4 2025.
  • 4,106 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Cravens & Co Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.